Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 3/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164822 | 0.85 | GAA (0.60) | GAAMAPTAHRCDC25B | |
| SCHEMBL3256484 | 0.85 | GAA (0.60) | GAAMAPTAHRCDC25B | |
| SCHEMBL6246219 | 0.85 | GAA (0.60) | GAAMAPTAHRCDC25B | |
| Water SCHEMBL28741688 | 0.84 | GAA (0.58) | GAAMAPTAHRCDC25B | |
| Hydrochloric Acid SCHEMBL11071035 | 0.84 | GAA (0.58) | GAAMAPTAHRCDC25B | |
| SCHEMBL13889887 | 0.84 | GAA (0.42) | SIRT1SIRT2GAAMAPTAHR | |
| Hydrochloric Acid SCHEMBL22617355 | 0.83 | GAA (0.57) | GAAMAPTAHRCDC25B | |
| SCHEMBL1760655 | 0.81 | GAA (0.42) | GAAMAPTHTR5A | |
| SCHEMBL5563634 | 0.80 | PDE5A (0.41) | GAAMAPTAHR | |
| SCHEMBL3256076 | 0.80 | PDE5A (0.41) | GAAMAPTAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8247432-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-21 | — | — | US | disclosed |
| CN-101307046-B | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-08-15 | — | — | CN | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY JOSEPH | 2011-09-15 | — | — | US | disclosed |
| US-7947713-B2 | (3-(4-phenyl-1H-imidazol-2-yl)-1,2,3,4-tetrahydro-isoquinoline; inactivation of endogenous neuropeptides such as cholecystokinis; eating disorders, obesity, psychotic syndromes and associated psychiatric disorders; chemical intermediates coupling | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| CN-101307046-A | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | CN | disclosed |
| CN-100400040-C | Tripeptidase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | CN | disclosed |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | BRESLIN HENRY J | 2008-05-08 | — | — | US | disclosed |
| EP-1392291-B1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-30 | — | — | EP | disclosed |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | BRESLIN HENRY J | 2006-12-07 | — | — | US | disclosed |
| US-7125891-B2 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-24 | — | — | US | disclosed |
| EP-1392291-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| CN-1471394-A | Tripeptidase inhibitors | ղɭҩҵ����˾ | 2004-01-28 | — | — | CN | disclosed |
| WO-2002036116-A9 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002036116-A2 | TRIPEPTIDYL PEPTIDASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034089-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | SIRT1 3937/4885SIRT2 3946/4885GAA 1598/4885 |
| US-20080108653-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | SIRT1 3532/4885SIRT2 4073/4885GAA 2335/4885 |
| US-20110224255-A1 | TRIPEPTIDYL PEPTIDASE INHIBITORS | CCKAR, CCKBR, VIP | SIRT1 3532/4885SIRT2 4073/4885GAA 2335/4885 |
| US-20060276509-A1 | Tripeptidyl peptidase inhibitors | CCKAR, CCKBR, VIP | SIRT1 3532/4885SIRT2 4073/4885GAA 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.